Implications of Microscopic Satellites of the Primary and Extracapsular Lymph Node Spread in Patients With High-Risk Melanoma: Pathologic Corollary of Eastern Cooperative Oncology Group Trial E1690
PURPOSE: To correlate the presence of extracapsular spread (ECS) of regional nodal metastases, and micrometastasis near the primary tumor, with disease outcome in the intergroup study E1690 in relation to the impact of recombinant interferon-alfa (rIFNα)-2b. PATIENTS AND METHODS: E1690 included 642...
Saved in:
Published in | Journal of clinical oncology Vol. 20; no. 8; pp. 2053 - 2057 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Baltimore, MD
American Society of Clinical Oncology
15.04.2002
Lippincott Williams & Wilkins |
Subjects | |
Online Access | Get full text |
ISSN | 0732-183X 1527-7755 |
DOI | 10.1200/JCO.2002.08.024 |
Cover
Abstract | PURPOSE: To correlate the presence of extracapsular spread (ECS) of regional nodal metastases, and micrometastasis near the primary tumor, with disease outcome in the intergroup study E1690 in relation to the impact of recombinant interferon-alfa (rIFNα)-2b.
PATIENTS AND METHODS: E1690 included 642 patients with American Joint Committee on Cancer stage IIB or III cutaneous melanoma. Patients were randomized into high- and low-dose rIFNα-2b treatment arms and an observation arm. Pathologic slides were reviewed for selected parameters from at least half of the subjects in all three arms. Evaluation of the primary tumor included notations regarding ulceration, mitotic activity, thickness, microscopic satellites (MS), and nodal ECS on a standardized pathology form. These data were collated in relation to relapse-free survival (RFS) and overall survival (OS) at 50 months’ follow-up and studied using Cox regression analysis.
RESULTS: Ulceration, mitotic activity, thickness, and size of tumor-bearing lymph nodes did not show a statistically significant correlation with either OS or RFS across all treatment arms. The presence of MS was correlated with RFS (P = .0008) and OS (P = .05). ECS correlated with RFS (hazard ratio = 1.44, P = .032) but not OS (P = .11).
CONCLUSION: The presence of MS (in 6% [18 of 308 patients]) had a significant adverse impact on both RFS (P = .0008) and OS (P = .053). Ulceration, mitotic activity, thickness, and number of positive lymph nodes had no significant effect on OS in this subset study (univariate or multivariate Cox analysis). The presence of ECS in lymph nodes had a significant adverse effect on RFS (P = .032) but not on OS. |
---|---|
AbstractList | To correlate the presence of extracapsular spread (ECS) of regional nodal metastases, and micrometastasis near the primary tumor, with disease outcome in the intergroup study E1690 in relation to the impact of recombinant interferon-alfa (rIFN alpha)-2b.PURPOSETo correlate the presence of extracapsular spread (ECS) of regional nodal metastases, and micrometastasis near the primary tumor, with disease outcome in the intergroup study E1690 in relation to the impact of recombinant interferon-alfa (rIFN alpha)-2b.E1690 included 642 patients with American Joint Committee on Cancer stage IIB or III cutaneous melanoma. Patients were randomized into high- and low-dose rIFN alpha-2b treatment arms and an observation arm. Pathologic slides were reviewed for selected parameters from at least half of the subjects in all three arms. Evaluation of the primary tumor included notations regarding ulceration, mitotic activity, thickness, microscopic satellites (MS), and nodal ECS on a standardized pathology form. These data were collated in relation to relapse-free survival (RFS) and overall survival (OS) at 50 months' follow-up and studied using Cox regression analysis.PATIENTS AND METHODSE1690 included 642 patients with American Joint Committee on Cancer stage IIB or III cutaneous melanoma. Patients were randomized into high- and low-dose rIFN alpha-2b treatment arms and an observation arm. Pathologic slides were reviewed for selected parameters from at least half of the subjects in all three arms. Evaluation of the primary tumor included notations regarding ulceration, mitotic activity, thickness, microscopic satellites (MS), and nodal ECS on a standardized pathology form. These data were collated in relation to relapse-free survival (RFS) and overall survival (OS) at 50 months' follow-up and studied using Cox regression analysis.Ulceration, mitotic activity, thickness, and size of tumor-bearing lymph nodes did not show a statistically significant correlation with either OS or RFS across all treatment arms. The presence of MS was correlated with RFS (P =.0008) and OS (P =.05). ECS correlated with RFS (hazard ratio = 1.44, P =.032) but not OS (P =.11).RESULTSUlceration, mitotic activity, thickness, and size of tumor-bearing lymph nodes did not show a statistically significant correlation with either OS or RFS across all treatment arms. The presence of MS was correlated with RFS (P =.0008) and OS (P =.05). ECS correlated with RFS (hazard ratio = 1.44, P =.032) but not OS (P =.11).The presence of MS (in 6% [18 of 308 patients]) had a significant adverse impact on both RFS (P =.0008) and OS (P =.053). Ulceration, mitotic activity, thickness, and number of positive lymph nodes had no significant effect on OS in this subset study (univariate or multivariate Cox analysis). The presence of ECS in lymph nodes had a significant adverse effect on RFS (P =.032) but not on OS.CONCLUSIONThe presence of MS (in 6% [18 of 308 patients]) had a significant adverse impact on both RFS (P =.0008) and OS (P =.053). Ulceration, mitotic activity, thickness, and number of positive lymph nodes had no significant effect on OS in this subset study (univariate or multivariate Cox analysis). The presence of ECS in lymph nodes had a significant adverse effect on RFS (P =.032) but not on OS. To correlate the presence of extracapsular spread (ECS) of regional nodal metastases, and micrometastasis near the primary tumor, with disease outcome in the intergroup study E1690 in relation to the impact of recombinant interferon-alfa (rIFN alpha)-2b. E1690 included 642 patients with American Joint Committee on Cancer stage IIB or III cutaneous melanoma. Patients were randomized into high- and low-dose rIFN alpha-2b treatment arms and an observation arm. Pathologic slides were reviewed for selected parameters from at least half of the subjects in all three arms. Evaluation of the primary tumor included notations regarding ulceration, mitotic activity, thickness, microscopic satellites (MS), and nodal ECS on a standardized pathology form. These data were collated in relation to relapse-free survival (RFS) and overall survival (OS) at 50 months' follow-up and studied using Cox regression analysis. Ulceration, mitotic activity, thickness, and size of tumor-bearing lymph nodes did not show a statistically significant correlation with either OS or RFS across all treatment arms. The presence of MS was correlated with RFS (P =.0008) and OS (P =.05). ECS correlated with RFS (hazard ratio = 1.44, P =.032) but not OS (P =.11). The presence of MS (in 6% [18 of 308 patients]) had a significant adverse impact on both RFS (P =.0008) and OS (P =.053). Ulceration, mitotic activity, thickness, and number of positive lymph nodes had no significant effect on OS in this subset study (univariate or multivariate Cox analysis). The presence of ECS in lymph nodes had a significant adverse effect on RFS (P =.032) but not on OS. PURPOSE: To correlate the presence of extracapsular spread (ECS) of regional nodal metastases, and micrometastasis near the primary tumor, with disease outcome in the intergroup study E1690 in relation to the impact of recombinant interferon-alfa (rIFNα)-2b. PATIENTS AND METHODS: E1690 included 642 patients with American Joint Committee on Cancer stage IIB or III cutaneous melanoma. Patients were randomized into high- and low-dose rIFNα-2b treatment arms and an observation arm. Pathologic slides were reviewed for selected parameters from at least half of the subjects in all three arms. Evaluation of the primary tumor included notations regarding ulceration, mitotic activity, thickness, microscopic satellites (MS), and nodal ECS on a standardized pathology form. These data were collated in relation to relapse-free survival (RFS) and overall survival (OS) at 50 months’ follow-up and studied using Cox regression analysis. RESULTS: Ulceration, mitotic activity, thickness, and size of tumor-bearing lymph nodes did not show a statistically significant correlation with either OS or RFS across all treatment arms. The presence of MS was correlated with RFS (P = .0008) and OS (P = .05). ECS correlated with RFS (hazard ratio = 1.44, P = .032) but not OS (P = .11). CONCLUSION: The presence of MS (in 6% [18 of 308 patients]) had a significant adverse impact on both RFS (P = .0008) and OS (P = .053). Ulceration, mitotic activity, thickness, and number of positive lymph nodes had no significant effect on OS in this subset study (univariate or multivariate Cox analysis). The presence of ECS in lymph nodes had a significant adverse effect on RFS (P = .032) but not on OS. |
Author | J. Richards J. Ibrahim L.E. Flaherty U.N.M. Rao J.M. Kirkwood |
Author_xml | – sequence: 1 givenname: U.N.M. surname: Rao fullname: Rao, U.N.M. organization: From the Departments of Pathology and Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, Melanoma Center, University of Pittsburgh Cancer Institute Pittsburgh, PA; Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA; Wayne State University, Harper-Grace Hospitals, Detroit, MI; and University of Chicago Medical Center, Chicago, IL – sequence: 2 givenname: J. surname: Ibrahim fullname: Ibrahim, J. organization: From the Departments of Pathology and Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, Melanoma Center, University of Pittsburgh Cancer Institute Pittsburgh, PA; Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA; Wayne State University, Harper-Grace Hospitals, Detroit, MI; and University of Chicago Medical Center, Chicago, IL – sequence: 3 givenname: L.E. surname: Flaherty fullname: Flaherty, L.E. organization: From the Departments of Pathology and Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, Melanoma Center, University of Pittsburgh Cancer Institute Pittsburgh, PA; Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA; Wayne State University, Harper-Grace Hospitals, Detroit, MI; and University of Chicago Medical Center, Chicago, IL – sequence: 4 givenname: J. surname: Richards fullname: Richards, J. organization: From the Departments of Pathology and Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, Melanoma Center, University of Pittsburgh Cancer Institute Pittsburgh, PA; Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA; Wayne State University, Harper-Grace Hospitals, Detroit, MI; and University of Chicago Medical Center, Chicago, IL – sequence: 5 givenname: J.M. surname: Kirkwood fullname: Kirkwood, J.M. organization: From the Departments of Pathology and Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, Melanoma Center, University of Pittsburgh Cancer Institute Pittsburgh, PA; Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA; Wayne State University, Harper-Grace Hospitals, Detroit, MI; and University of Chicago Medical Center, Chicago, IL |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13636678$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11956265$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kk9v1DAQxSNURLeFMzfkC9yy9Z_Ecbih1dIWbdmKFsHNcpxJ4-LEwU6A_YB8L5zuAhISp5Hs37zRvHknyVHvekiS5wQvCcX47N1qu4yVLrFYYpo9ShYkp0VaFHl-lCxwwWhKBPt8nJyEcI8xyQTLnyTHhJQ5pzxfJD8vu8EarUbj-oBcg66M9i5oNxiNbtQI1poRHn7GFtC1N53yO6T6Gq1_jF5pNYTJKo82u25o0XtXA7oZPKgamR5dR13ox4A-mbFFF-auTT-Y8AVdgVW969TrmWiddXdx2sp5Z-2sHoetVRjB9_HRDeCjzDdA217P6A6dezcN6NYbZdGa8BI_TR43ygZ4dqinyce369vVRbrZnl-u3mxSzfJsTJu6xAoqEJQRIBhwTfKyqlhdCUXLWhCRiYZSjrnWJQfKmcjqRmteQp0VTcVOk1d73cG7rxOEUXYm6OiR6sFNQRaE4wyLLIIvDuBUdVDLYe-b_G18BF4eABW0so1XvTbhL8c447wQkcv33HyV4KGR2owP14rmGysJlnMQZAyCnIMgsZAxCLHv7J--P9L_7Tjs1sYzfTceZOiUtXEBKu-1o1iKyOeM_QJ5iMR_ |
CitedBy_id | crossref_primary_10_1245_s10434_018_7006_4 crossref_primary_10_1016_j_jaad_2011_04_031 crossref_primary_10_1016_j_jaad_2022_10_027 crossref_primary_10_1038_s41379_020_0500_9 crossref_primary_10_1002_cncr_24627 crossref_primary_10_1016_S1578_2190_11_70800_9 crossref_primary_10_1016_j_jaad_2018_08_055 crossref_primary_10_3389_fcell_2023_1290696 crossref_primary_10_1111_j_1365_2559_2012_04279_x crossref_primary_10_1245_s10434_013_3092_5 crossref_primary_10_1097_DSS_0000000000001643 crossref_primary_10_1016_j_ejso_2014_03_002 crossref_primary_10_1245_s10434_009_0353_4 crossref_primary_10_1016_j_ad_2011_01_001 crossref_primary_10_1016_j_cps_2009_07_001 crossref_primary_10_4065_82_4_490 crossref_primary_10_1002_cam4_1320 crossref_primary_10_1016_j_mcna_2021_04_005 crossref_primary_10_1200_JCO_2009_23_4799 crossref_primary_10_1080_17512433_2019_1689121 crossref_primary_10_1245_s10434_011_1986_7 crossref_primary_10_1093_jnci_djaa012 crossref_primary_10_3390_jcm10214994 crossref_primary_10_1007_s40291_018_0318_z crossref_primary_10_1007_s00330_021_07852_7 crossref_primary_10_1016_j_det_2012_04_007 crossref_primary_10_5858_2003_127_e365_PQCAPL crossref_primary_10_1080_14737140_2018_1489246 crossref_primary_10_1309_AJCPTXMEFOVYWDA6 crossref_primary_10_1016_j_ejso_2020_09_005 crossref_primary_10_1097_DAD_0000000000002817 crossref_primary_10_1016_j_pathol_2015_12_005 crossref_primary_10_1038_modpathol_3800517 crossref_primary_10_1016_j_coms_2021_12_001 crossref_primary_10_1016_j_ejca_2019_03_010 crossref_primary_10_3322_caac_21409 crossref_primary_10_1245_s10434_013_3388_5 crossref_primary_10_3390_cancers16050895 crossref_primary_10_1016_j_ctrv_2020_102032 crossref_primary_10_1590_S1677_5538_IBJU_2013_06_08 |
Cites_doi | 10.1200/JCO.1995.13.9.2361 10.1002/(SICI)1097-0347(199710)19:7<589::AID-HED5>3.0.CO;2-3 10.1200/JCO.2001.19.16.3622 10.1002/1097-0142(20000715)89:2<453::AID-CNCR34>3.0.CO;2-V 10.1002/1097-0142(19851001)56:7<1597::AID-CNCR2820560722>3.0.CO;2-5 10.1016/0002-9610(86)90307-7 10.1288/00005537-199105000-00010 10.1002/jso.2930250404 10.1200/JCO.2000.18.12.2444 10.1097/00000658-199111000-00014 10.1097/00000658-199110000-00013 10.1001/archotol.1981.00790480001001 10.1111/j.1365-2273.1982.tb01581.x 10.1007/BF02071524 10.1001/archderm.134.8.983 10.1097/00005537-200009000-00017 10.1046/j.1365-2168.2000.01439.x 10.1001/archsurg.1991.01410360031006 10.1016/S0025-7125(05)70418-1 10.1177/000313480006600602 10.1002/(SICI)1097-0142(19990815)86:4<617::AID-CNCR10>3.0.CO;2-S 10.1002/1097-0142(19840515)53:10<2183::AID-CNCR2820531029>3.0.CO;2-9 10.1177/000348949910800710 10.1097/00000658-198107000-00019 10.1007/BF02303638 10.1080/028418699431113 10.1002/1097-0142(19950615)75:12<2885::AID-CNCR2820751215>3.0.CO;2-3 10.1016/S1072-7515(00)00313-6 10.1046/j.1365-2559.1998.00523.x 10.1007/s10434-000-0469-z 10.1200/JCO.2001.19.16.3635 10.1097/00000658-199008000-00002 10.1002/(SICI)1097-0142(20000315)88:6<1484::AID-CNCR29>3.0.CO;2-D 10.1016/S0169-5002(97)00072-X |
ContentType | Journal Article |
Copyright | 2002 INIST-CNRS |
Copyright_xml | – notice: 2002 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1200/JCO.2002.08.024 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1527-7755 |
EndPage | 2057 |
ExternalDocumentID | 11956265 13636678 10_1200_JCO_2002_08_024 jco20_8_2053 |
Genre | Research Support, U.S. Gov't, P.H.S Clinical Trial Randomized Controlled Trial Journal Article |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: CA39229 – fundername: NCI NIH HHS grantid: CA66636 – fundername: NCI NIH HHS grantid: CA14028 – fundername: NCI NIH HHS grantid: CA21115 – fundername: NCI NIH HHS grantid: CA32102 – fundername: NCI NIH HHS grantid: CA23318 |
GroupedDBID | - 08R 0R 2WC 34G 39C 3O- 4.4 53G 55 5GY 5RE 8F7 8WZ A6W AARDX AAWTL AAYEP ABFLS ABOCM ACGFS ADBIT AENEX AFFNX ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AWKKM AZFZN CS3 DIK EBS EJD EX3 F5P FD8 FEDTE FH7 GJ H13 HVGLF HZ IH2 KQ8 L7B N9A O9- OK1 OVD OWW P2P RHI RUC SJN SV3 TWZ UDS VH1 WH7 WOQ WOW X7M YCJ ZA5 ZGI --- .55 .GJ 08G 0R~ 18M AAKAS AAYXX ABBLC ABJNI ACGFO ADZCM AEGXH AI. AIAGR C45 CITATION F9R FBNNL HZ~ MJL N4W QTD R1G RLZ TEORI TR2 UHU VVN YFH YQY 08P 29K 5VS AAQOH AAQQT ACGUR ADBBV BAWUL BYPQX D-I GX1 IPNFZ IQODW J5H K-O LSO NTWIH RIG CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c354t-fd90aebe8231e10e0d159bb3db8a29d81848f22606cc96e26384dfcc69ed47fb3 |
ISSN | 0732-183X |
IngestDate | Fri Jul 11 09:45:27 EDT 2025 Sat Sep 28 07:48:04 EDT 2024 Mon Jul 21 09:14:40 EDT 2025 Tue Jul 01 02:23:47 EDT 2025 Thu Apr 24 22:55:30 EDT 2025 Tue Jan 05 20:17:23 EST 2021 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Keywords | Antineoplastic agent Human Skin disease Prognosis Lymph node Cytokine Melanoma Malignant lymphadenopathy Malignant hemopathy Malignant tumor Metastasis Regional Extracapsular Treatment Interferon alpha 2b Immunotherapy Micrometastasis Skin |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c354t-fd90aebe8231e10e0d159bb3db8a29d81848f22606cc96e26384dfcc69ed47fb3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
PMID | 11956265 |
PQID | 71604084 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_71604084 pubmed_primary_11956265 pascalfrancis_primary_13636678 crossref_citationtrail_10_1200_JCO_2002_08_024 crossref_primary_10_1200_JCO_2002_08_024 highwire_smallpub2_jco20_8_2053 |
ProviderPackageCode | RHI CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2002-04-15 |
PublicationDateYYYYMMDD | 2002-04-15 |
PublicationDate_xml | – month: 04 year: 2002 text: 2002-04-15 day: 15 |
PublicationDecade | 2000 |
PublicationPlace | Baltimore, MD |
PublicationPlace_xml | – name: Baltimore, MD – name: United States |
PublicationTitle | Journal of clinical oncology |
PublicationTitleAlternate | J Clin Oncol |
PublicationYear | 2002 |
Publisher | American Society of Clinical Oncology Lippincott Williams & Wilkins |
Publisher_xml | – name: American Society of Clinical Oncology – name: Lippincott Williams & Wilkins |
References | R9-107008 R8-107008 R7-107008 R26-107008 R17-107008 R18-107008 R33-107008 R34-107008 R35-107008 R36-107008 R16-107008 R19-107008 R15-107008 R14-107008 R31-107008 R38-107008 R22-107008 R23-107008 R30-107008 R37-107008 R32-107008 R24-107008 R28-107008 R20-107008 R21-107008 R25-107008 R27-107008 R29-107008 R12-107008 R6-107008 R11-107008 R13-107008 R1-107008 R2-107008 R3-107008 R4-107008 R5-107008 R10-107008 |
References_xml | – ident: R9-107008 doi: 10.1200/JCO.1995.13.9.2361 – ident: R16-107008 doi: 10.1002/(SICI)1097-0347(199710)19:7<589::AID-HED5>3.0.CO;2-3 – ident: R11-107008 doi: 10.1200/JCO.2001.19.16.3622 – ident: R34-107008 doi: 10.1002/1097-0142(20000715)89:2<453::AID-CNCR34>3.0.CO;2-V – ident: R22-107008 doi: 10.1002/1097-0142(19851001)56:7<1597::AID-CNCR2820560722>3.0.CO;2-5 – ident: R1-107008 doi: 10.1016/0002-9610(86)90307-7 – ident: R38-107008 – ident: R20-107008 doi: 10.1288/00005537-199105000-00010 – ident: R10-107008 doi: 10.1002/jso.2930250404 – ident: R29-107008 doi: 10.1200/JCO.2000.18.12.2444 – ident: R2-107008 doi: 10.1097/00000658-199111000-00014 – ident: R5-107008 – ident: R8-107008 doi: 10.1097/00000658-199110000-00013 – ident: R21-107008 doi: 10.1001/archotol.1981.00790480001001 – ident: R18-107008 doi: 10.1111/j.1365-2273.1982.tb01581.x – ident: R3-107008 – ident: R17-107008 doi: 10.1007/BF02071524 – ident: R30-107008 doi: 10.1001/archderm.134.8.983 – ident: R33-107008 doi: 10.1097/00005537-200009000-00017 – ident: R15-107008 doi: 10.1046/j.1365-2168.2000.01439.x – ident: R27-107008 doi: 10.1001/archsurg.1991.01410360031006 – ident: R37-107008 doi: 10.1016/S0025-7125(05)70418-1 – ident: R36-107008 doi: 10.1177/000313480006600602 – ident: R6-107008 doi: 10.1002/(SICI)1097-0142(19990815)86:4<617::AID-CNCR10>3.0.CO;2-S – ident: R26-107008 doi: 10.1002/1097-0142(19840515)53:10<2183::AID-CNCR2820531029>3.0.CO;2-9 – ident: R19-107008 doi: 10.1177/000348949910800710 – ident: R28-107008 doi: 10.1097/00000658-198107000-00019 – ident: R4-107008 doi: 10.1007/BF02303638 – ident: R31-107008 doi: 10.1080/028418699431113 – ident: R24-107008 doi: 10.1002/1097-0142(19950615)75:12<2885::AID-CNCR2820751215>3.0.CO;2-3 – ident: R7-107008 doi: 10.1016/S1072-7515(00)00313-6 – ident: R14-107008 doi: 10.1002/jso.2930250404 – ident: R32-107008 doi: 10.1046/j.1365-2559.1998.00523.x – ident: R35-107008 doi: 10.1007/s10434-000-0469-z – ident: R12-107008 doi: 10.1200/JCO.2001.19.16.3635 – ident: R13-107008 doi: 10.1097/00000658-199008000-00002 – ident: R25-107008 doi: 10.1002/(SICI)1097-0142(20000315)88:6<1484::AID-CNCR29>3.0.CO;2-D – ident: R23-107008 doi: 10.1016/S0169-5002(97)00072-X |
SSID | ssj0014835 |
Score | 1.9064752 |
Snippet | PURPOSE: To correlate the presence of extracapsular spread (ECS) of regional nodal metastases, and micrometastasis near the primary tumor, with disease outcome... To correlate the presence of extracapsular spread (ECS) of regional nodal metastases, and micrometastasis near the primary tumor, with disease outcome in the... |
SourceID | proquest pubmed pascalfrancis crossref highwire |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2053 |
SubjectTerms | Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Humans Immunotherapy Interferon-alpha - therapeutic use Lymphatic Metastasis Medical sciences Melanoma - drug therapy Melanoma - pathology Mitotic Index Neoplasm Staging Pharmacology. Drug treatments Recombinant Proteins Skin Neoplasms - drug therapy Skin Neoplasms - pathology Survival Analysis Ulcer |
Title | Implications of Microscopic Satellites of the Primary and Extracapsular Lymph Node Spread in Patients With High-Risk Melanoma: Pathologic Corollary of Eastern Cooperative Oncology Group Trial E1690 |
URI | http://jco.ascopubs.org/content/20/8/2053.abstract https://www.ncbi.nlm.nih.gov/pubmed/11956265 https://www.proquest.com/docview/71604084 |
Volume | 20 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbhMxELXaIiFeEJRbCxQ_oAop3WXrvYY3FKVqgTSlTUXfVl7bqwYlu1GTSoT_47-Ysb2XFCouL1G12YsbnzOeWc-cIeS1En6cdGXoCOkLJ8jz0OFg9gDLYaJy3BvSQtqD4-jwPPhwEV6srW-3spauF5krvv-2ruR_ZhWOwbxilew_zGx9UzgAf8P8wifMMHz-1RwftdPBMZcFs-uwzmQsOmdca20ujKgsupcnVlgCX5X3vy2uuOAQImMW6qclzGnnuJSqczYDLxL1mFC8f6zL377gq1rMB3FOMQ99oCa8KKe6pw-cY60nGJYrhJTZse9zrb8AB8uZstriw0IYvSfz_muk24X0cf_sFge5Ltos7ZUVOM7dY3fgdk55Wef_uJ0jCPsvx9M6wcjtu52DCb9E7eDWaVZIYPVtB8ONG1Pv2SowQMtnc1oxZ6UazbA9GmNCY585YLQuzGpnTTyLIaYw4sDVGsC8FtaTtkH3jJbxLysNM020e0Od5qJlYE0xeAt3s6kGHqrqQdwYNktulWZwYyWu8yO_ipJ5aZLi09fJHRbHOgXh4-dmhyxITPPY6j-0slUwmLc3BoW6uHYEq85XJYiN-cB8Dr9gbnq53B5saadr9IDct2Cg7w30H5I1VWySuwObD7JJdk-M8vpyj46aQsL5Ht2lJ40m-_IR-dGmCi1z2qIKbaiC3wBVqKUKBarQFapQTRWKVKGGKnRc0IoqFKlCa6rQiirvaEMUWhMFH2aJQltEoRXAqCYK1UShmiiPyflBf9Q7dGwHE0f4YbBwctn1OJhJ3GtX-57yJEQPWebLLOGsK8FZDpIcAiAvEqIbKQaLYSBzIaKukkGcZ_4TslGUhXpGqJQJz7IwkoJnQb6f8yBU4K13JVNxHItgi7jV1KbCyvtjl5lJimE-wz3r3hCbzrIU-84yuOBNfcHM_Kq3n_qqwko6n_LJBDDB0jZIt8jOCoSaO_qRH4FDDLeoMJXCAoa7krxQ5fU8BWiDI5HAQ54aqDXXWtRu__Hxz8m9xli8IBuLq2v1EoKFRbajWfMT9zgZHg |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Implications+of+Microscopic+Satellites+of+the+Primary+and+Extracapsular+Lymph+Node+Spread+in+Patients+With+High-Risk+Melanoma%3A+Pathologic+Corollary+of+Eastern+Cooperative+Oncology+Group+Trial+E1690&rft.jtitle=Journal+of+clinical+oncology&rft.au=U.N.M.+Rao&rft.au=J.+Ibrahim&rft.au=L.E.+Flaherty&rft.au=J.+Richards&rft.date=2002-04-15&rft.pub=American+Society+of+Clinical+Oncology&rft.issn=0732-183X&rft.eissn=1527-7755&rft.volume=20&rft.issue=8&rft.spage=2053&rft_id=info:doi/10.1200%2FJCO.2002.08.024&rft_id=info%3Apmid%2F11956265&rft.externalDBID=n%2Fa&rft.externalDocID=jco20_8_2053 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |